Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 6 7 8 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth 2021-09-16
Anjarium Biosciences–Citadel: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Surveyor Capital 2021-09-16
Anjarium Biosciences–Gimv: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Gimv 2021-09-16
Anjarium Biosciences–Huntsworth: public relations, 202109 service existent by Medistrava Consulting 2021-09-16
Anjarium Biosciences–Omega Funds: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Omega Funds 2021-09-16
Anjarium Biosciences–Pfizer: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Pfizer Ventures 2021-09-16
Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv 2021-09-16
BRAIN Biotech–SEVERAL: investment, 202109 capital increase €19.6m with 1.99m new shares at €9.85/share to institutional investors 2021-09-15
Evotec–Biognosys: MS-based proteomics, 202109– collab integration of Spectronaut proteomics data analys into drug discovery + clinical proteomics 2021-09-14
Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets 2021-09-09
TIB Molbiol–Roche: investment, 202109–202112 acquisition 100% of TIB Mobiol Group by Roche 2021-09-09
ImmunOs Therapeutics–Akampion: public relations, 202109 service existent by Akampion 2021-09-01
Oviva–Albion Ventures: investment, 202109 financing round Series C totalling $80m incl existing + co-investor AlbionVC 2021-09-01
Oviva–Earlybird: investment, 202109 financing round Series C totalling $80m incl existing + co-investor Earlybird 2021-09-01
Oviva–F-Prime: investment, 202109 financing round Series C totalling $80m incl existing + co-investor F-Prime Capital 2021-09-01
Oviva–Fidelity: investment, 202109 financing round Series C totalling $80m incl existing + co-investor Eight Roads Ventures 2021-09-01
Oviva–MedTech Innovation Partners: investment, 202109 financing round Series C totalling $80m incl existing + co-investor MTIP 2021-09-01
Oviva–SEVERAL: investment, 202109 financing round Series C $80m co-led by Sofina + Temasek 2021-09-01
Oviva–Sofina: investment, 202109 financing round Series C totalling $80m incl co-lead investor Sofina 2021-09-01
Oviva–Temasek: investment, 202109 financing round Series C totalling $80m incl co-lead investor Temasek 2021-09-01
Comet Therapeutics–ABP (NL): investment, 202108 existing investor Inkef Capital at time of sale of Comet Tx to VectivBio 2021-08-31
Comet Therapeutics–Canaan Partners: investment, 202108 existing investor Canaan at time of sale of Comet Tx to VectivBio 2021-08-31
Comet Therapeutics–Mission BioCapital: investment, 202108 existing investor Mission BioCapital at time of sale of Comet Tx to VectivBio 2021-08-31
Comet Therapeutics–Sofinnova: investment, 202108 existing investor Sofinnova Partners at time of sale of Comet Tx to VectivBio 2021-08-31
Comet Therapeutics–VectivBio: investment, 202108–202109 acquisition in cash + shares upfront plus milestones in cash or equity 2021-08-31
NürnbergMesse–Messe Stuttgart: T4M trade show, 202108 acquistion of T4M event from Messe Stuttgart by MedtecLIVE GmbH 2021-08-30
Biognosys–ETH Zürich: LiP technology, 202108 collab developm + excl license from Institute of Systems Biology 2021-08-27
HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami 2021-08-26
Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital 2021-08-25
Cardior Pharmaceuticals–BioMedPartners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BioMedPartners 2021-08-25
Cardior Pharmaceuticals–BMS: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BMS 2021-08-25
Cardior Pharmaceuticals–Fund+: investment, 202108 financing round Series B totalling €64m incl new + co-investor Fund+ 2021-08-25
Cardior Pharmaceuticals–Germany (govt): investment, 202108 financing round Series B totalling €64m incl new + co-investor Coparion 2021-08-25
Cardior Pharmaceuticals–Hadean Ventures: investment, 202108 financing round Series B totalling €64m incl new + co-investor Hadean Ventures 2021-08-25
Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 202108 financing round Series B totalling €64m incl existing + co-investor HTGF 2021-08-25
Cardior Pharmaceuticals–Life Sciences Partners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor LSP 2021-08-25
Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital 2021-08-25
Cardior Pharmaceuticals–Sunstone Life Science: investment, 202108 financing round Series B totalling €64m incl new + co-investor Sunstone 2021-08-25
Cardior Pharmaceuticals–Trophic Communications: public relations, 202108 service existent by Trophic Communications 2021-08-25
FarmInsect–5x Ventures: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor 5x Ventures 2021-08-17
FarmInsect–Bavaria (govt): investment, 202108 2nd seed financing round totalling 7-digit € incl co-lead investor Bayern Kapital 2021-08-17
FarmInsect–Genea Invest: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor Genea Invest 2021-08-17
FarmInsect–High-Tech Gründerfonds: investment, 202108 2nd seed financing round totalling 7-digit € incl co-lead investor HTGF 2021-08-17
FarmInsect–Industrial Innovators Initiative: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor III 2021-08-17
FarmInsect–OTHER: investment, 202108 2nd seed financing round totalling 7-digit € incl business angels as co-investors 2021-08-17
FarmInsect–SEVERAL: investment, 202108 2nd seed financing round 7-digit € co-led by HTGF + Bayern Kapital 2021-08-17
Bayer–Berkeley Lights: plant research, 202108 collab multi-year €na RnD seeds and traits using Berkeley Lights Platform 2021-08-11
Visus Therapeutics–Life Sciences Partners: investment, 202108 financing round totalling $20m in preferred stock incl new + lead investor LSP 2021-08-10
Visus Therapeutics–SEVERAL: investment, 202108 financing round $20m in preferred stock led by new investor LSP 2021-08-10
OncXerna Therapeutics–Qiagen: molecular companion diagnostics, 202108– collab developm Xerna TME panel as NGS CDx for navicixizumab 2021-08-09
Qiagen–OncXerna Therapeutics: molecular companion diagnostics, 202108– license non-excl to Xerna TME panel as NGS CDx for Qiagen 2021-08-09
SolasCure–Seneca Partners: investment, 201808–202108 financing round Series A totalling £15m incl co-investor Seneca Partners 2021-08-09
Vividion Therapeutics–Bayer: investment, 202108– acquisition $1.5b upfront + $500k milestones 2021-08-05
Evotec–SEVERAL: investment, 202108–202111 public offering $435m+$65.14m with 20m+2.995m ADSs at $21.75/ADS US listing at Nasdaq 2021-08-02
T-Knife–SEVERAL: investment, 202108 financing round Series B $110m led by new investor Fidelity Management and Research 2021-08-02
Nebion–Immunai: investment, 202107 acquisition of Nebion AG by Immunai 2021-07-29
Topas Therapeutics–BioMedPartners: investment, 202107 financing round Series B extension €18m incl existing investor BioMedPartners 2021-07-29
Topas Therapeutics–Boehringer: investment, 202107 financing round Series B extension €18m incl existing investor BIVF 2021-07-29
Topas Therapeutics–EMBL: investment, 202107 financing round Series B extension €18m incl existing investor EMBL Ventures 2021-07-29
Topas Therapeutics–Epidarex Capital: investment, 202107 financing round Series B extension €18m incl existing investor Epidarex Capital 2021-07-29
Topas Therapeutics–Evotec: investment, 202107 financing round Series B extension €18m incl existing investor Evotec 2021-07-29
Topas Therapeutics–Gimv: investment, 202107 financing round Series B extension €18m incl existing investor Gimv 2021-07-29
Topas Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €18m bringing total round to €40m incl all existing investors 2021-07-29
Topas Therapeutics–Vesalius Biocapital: investment, 202107 financing round Series B extension €18m incl existing investor Vesalius Biocapital III 2021-07-29
Xell AG–Sartorius: investment, 202107 acquisition €50m plus two revenue-based earn-out components in 2022 to 2025 2021-07-29
Evitria–Atlas Antibodies: investment, 202107 acquisition of Evitria by Atlas Antibodies AB 2021-07-28
HMNC–SEVERAL: credit, 202107 convertible debt financing €9m from renowned family offices incl Maschmeyer + Jahr + Gutmann 2021-07-28
Nuvisan–ALS Ltd: investment, 202207 strategic investment acquiring 49% stake in Nuvisan to expand ALS Life Sciences network 2021-07-28
Sartorius–BRAIN Biotech: genome editing technology, 202107– collab research on CRISPR Cas-nucleases (BECs) 2021-07-28
Artios Pharma–Merck (DE): investment, 202107 financing round Series C totalling £110m ($153m) incl existing + co-investor M Ventures 2021-07-27
Artios Pharma–SEVERAL: investment, 202107 financing round Series C £110m ($153m) co-led by Omega Funds + TCG X 2021-07-27
Cevec–North Rhine-Westphalia (govt): investment, 202107 growth financing round incl investor NRW.Bank 2021-07-27
Cevec–SEVERAL: investment, 202107 growth financing round with investor NRW.Bank et al 2021-07-27
Axa–SEVERAL: investment, 202107 raising of €1.9b equity by AXA IM Alts to invest in European Life Sciences primarily via Kadans Science Partner 2021-07-26
Relief Therapeutics–SEVERAL: investment, 202107 private placement CHF15m with 71.4m common stock at CHF0.21/share to two US institutional investors 2021-07-26
Sophia Genetics–SEVERAL: investment, 202107 US IPO $234m+$35.1m with 13m+1.95m ordinary shares at $18/Share at Nasdaq Global Select Market 2021-07-22
3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED 2021-07-20
NanoSyrinx–Merck (DE): investment, 202107 seed financing round totalling £6.2m incl existing + co-lead investor M Ventures 2021-07-19
NanoSyrinx–SEVERAL: investment, 202107 seed financing round £6.2m co-led by Octopus Ventures + M Ventures 2021-07-19
Dopavision–Akampion: public relations, 202107 service existent by Akampion 2021-07-14
Dopavision–Boehringer: investment, 202107 financing round Series A totalling €12m incl existing + co-investor BIVF 2021-07-14
Dopavision–BPCE: investment, 202107 financing round Series A totalling €12m incl new + lead investor Seventure Partners 2021-07-14
Dopavision–Eternity.Health: investment, 202107 financing round Series A totalling €12m incl existing + co-investor Ababax Health 2021-07-14
Dopavision–Novartis: investment, 202107 financing round Series A totalling €12m incl new + co-investor Novartis Pharmaceuticals 2021-07-14
Dopavision–SEVERAL: investment, 202107 financing round Series A €12m led by new investor Seventure Partners 2021-07-14
Immunic–SEVERAL: investment, 202107 underwritten public offering $45m with 4.5m shares common stock at $10/share 2021-07-14
InfanDx–SEVERAL: investment, 202107 financing round Series A first closing €4m from new investor Alluti GmbH + existing investors 2021-07-13
Vectura–Philip Morris: investment, 202107– acquisition recommended cash tender offer £852m at150p/share 2021-07-09
Theolytics–Merck (DE): investment, 202107 financing round Series A expansion incl new investor M Ventures 2021-07-08
Theolytics–Otsuka: investment, 202107 financing round Series A expansion incl existing investor Taiho Ventures 2021-07-08
Theolytics–SEVERAL: investment, 202107 financing round Series A expansion incl new investor M Ventures 2021-07-08
Theolytics–Univ Oxford: investment, 202107 financing round Series A expansion incl existing investor Univ Oxford 2021-07-08
Cutanos–High-Tech Gründerfonds: investment, 202107 1st financing round incl investor HTGF 2021-07-05
Cutanos–IST Cube: investment, 202107 1st financing round incl investor IST Cube 2021-07-05
Cutanos–Khanu Management: investment, 202107 1st financing round incl investor KHAN Technology Transfer Fund I 2021-07-05
Cutanos–OTHER: investment, 202107 1st financing round incl a private investor 2021-07-05
Cutanos–SEVERAL: investment, 202107 1st financing round with KHAN-I + HTGF + IST Cube + another private investor 2021-07-05
CellGenix–Sartorius: investment, 202107 acquisition 51% share for €100m cash by SSB with planned acquisition of remaining shares until 2026 2021-07-02
Fertin Pharma–Philip Morris: investment, 202107– acquisition DKK5.1b ($820m) from EQT + Bagger-Sørensen ANNOUNCED 2021-07-01
Inova Software–Carlyle: investment, 202107 growth equity investment €60m by CETP IV with Carlyle becoming largest shareholder 2021-07-01
next pagenext page 1 2 3 ... 6 7 8 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top